Pharmacothérapies actuelles et immunothérapie dans l'addiction à la cocaïne

Translated title of the contribution: Current pharmacotherapies and immunotherapy in cocaine addiction

Laurent Karila, Aviv Weinstein, Amine Benyamina, Sarah Coscas, Claire Leroy, Florence Noble, William Lowenstein, Henri Jean Aubin, Jean Pierre Lépine, Michel Reynaud

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations


Cocaine is more and more used and abused in France. Cocaine dependence is quite serious and is associated with numerous adverse health consequences. No effective pharmacotherapy for cocaine dependence is yet available. Recent advances in neurobiology, brain imaging and some clinical trials suggest that certain medications that modulate GABAergic, dopaminergic, and glutamatergic systems, as well as immunotherapy, show promise in the treatment of cocaine addiction. Recent controlled clinical studies have tested some of these drugs, which act on the various neurobiological circuits modified by cocaine exposure and clinically improve patients' symptoms. Pharmacological agents such as modafinil, GABAergic agents (baclofen, topiramate, tiagabin, and vigabatrin), disulfiram, aripiprazole, N-acetylcysteine and cocaine vaccine seem very promising in the treatment of cocaine dependence. However, this must be confirmed in larger patient populations.

Translated title of the contributionCurrent pharmacotherapies and immunotherapy in cocaine addiction
Original languageFrench
Pages (from-to)689-698
Number of pages10
JournalPresse Medicale
Issue number4 PART 2
StatePublished - Apr 2008
Externally publishedYes


Dive into the research topics of 'Current pharmacotherapies and immunotherapy in cocaine addiction'. Together they form a unique fingerprint.

Cite this